Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3086)	8/24/2020 1:25:32 AM
From: CuttingEdge Bio	Read Replies (1) \| Respond to of 3557

I'm a little confused here. How are they magically creating a formulation that cuts down on the needed volume of 2mL or 16mL injection in these various scenarios? I think your other alternative of a much more potent cocktail would be the more likely scenario enabling this, but I also don't see why it would be so much more potent? It's not like they didn't optimize the choice of antibodies for the Ebola and MERS cocktails too, just like they did here. Good quality antibodies won't behave that differently.